The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Researchers at the Center for Life Sciences at the Paul Scherrer Institute PSI have for the first time identified structural ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Like why, for example, having diabetes can put you at ... (GLP-1), a hormone from a family of chemical messengers called the incretins, which Belgian physiologist Jean LaBarre first purified ...

As a GLP-1/glucagon dual receptor agonist, pemvidutide offers a differentiated mechanism of action compared to other incretin-based therapies currently on the market or in development. The drug ...

2 Consequently, GLP-1 has become the foundational compound for incretin-based therapies (e.g., GLP-1 receptor agonists), which also provide additional benefits of appetite suppression and reduced food ...

The most prominent example is the use of GLP-1 receptor agonists in the past two decades, starting with their initial approval by the Food and Drug Administration in 2005. GLP-1 receptor agonists ...

Although DPP-4 cleaves dozens of regulatory peptides and chemokines in vitro, studies of mice with genetic inactivation of incretin receptors demonstrate that GIP and GLP-1 receptor-dependent ...

"These findings could be particularly important for understanding the heart health effects of fat and muscle-modifying incretin-based ... of glucagon-like peptide-1 receptor agonists." ...

Study of 2.4 million participants reveals potential advantages for cardiometabolic and psychiatric conditions alongside increased risks of gastrointestinal and musculoskeletal issues Study ...

Moreover, the company is exploring the development of TSHR NAM programs aimed at Graves’ disease and thyroid eye disease, as well as oral small molecule incretin receptor agonists for metabolic ...